Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Neoadjuvant therapy is now standard in NSCLC – but can every patient complete the journey in the real world?
Clinical trials are promising real-world success, however, depends on:
- Careful patient selection
- Rigorous performance status assessment
- Early surgical planning
- Strong multidisciplinary tumor board coordination
In neoadjuvant strategies, the goal is not only response – it is safely delivering the patient to surgery.
Timing matters. Logistics matter. Biology matters.”
Read the full article here.
Other OncoDaily articles featuring Prof. Ahmet Dirican.